influenza
viru
infect
caus
excess
hospit
death
among
adult
season
peak
pandem
among
patient
infect
present
rapidli
progress
pneumonia
present
pneumonia
caus
influenza
viru
infect
complic
acut
respiratori
distress
syndrom
ard
death
rate
patient
high
patient
infect
rate
pneumonia
high
patient
admit
intens
care
unit
icu
icu
develop
ard
influenza
virusinduc
pneumonia
relat
uncontrol
respons
immun
system
corticosteroid
report
reduc
mortal
patient
communitybas
pneumonia
patient
lifethreaten
respiratori
failur
associ
influenza
pneumonia
also
commonli
receiv
corticosteroid
anim
model
studi
found
corticosteroid
treatment
decreas
mortal
amelior
acut
lung
injuri
induc
influenza
pneumonia
steroid
might
play
role
inhibit
inflamm
via
mechan
reduc
overproduct
proinflammatori
cytokineschemokin
excess
activ
lymphocyt
may
result
sever
lung
damag
delay
recoveri
howev
result
clinic
studi
effect
corticosteroid
remain
controversi
studi
diaz
studi
use
corticosteroid
therapi
significantli
associ
mortal
other
studi
brunbuisson
earli
corticosteroid
therapi
found
potenti
harm
patient
influenza
pneumonia
therefor
base
controversi
find
relat
corticosteroid
use
adult
patient
influenza
pneumonia
conduct
systemat
review
metaanalysi
publish
trial
compar
mortal
influenza
pneumonia
patient
receiv
corticosteroid
therapi
aim
identifi
role
corticosteroid
influenc
clinic
outcom
patient
influenza
pneumonia
literatur
search
conduct
pubm
embas
medlin
cochran
central
regist
control
trail
central
inform
scienc
institut
isi
web
scienc
databas
use
combin
follow
key
word
glucocorticoid
corticosteroid
steroid
cortison
hydrocortison
prednisolon
methylprednisolon
prednison
dexamethason
triamcinolon
influenza
pneumonia
viral
pneumonia
without
limit
either
public
type
languag
search
also
limit
studi
publish
januari
refer
list
identifi
articl
also
screen
manual
search
elig
clinic
trial
identifi
base
follow
criteria
subject
enrol
studi
includ
patient
influenza
pneumonia
patient
divid
experiment
group
corticosteroid
appli
control
group
patient
assign
receiv
corticosteroid
outcom
includ
limit
mortal
mechan
ventil
mv
day
length
stay
icu
icu
lo
rate
secondari
infect
exclud
studi
perform
anim
patient
year
old
publish
noncontrol
studi
review
case
report
two
independ
investig
ynn
bml
review
titl
abstract
discard
duplic
noncontrol
studi
full
text
remain
studi
screen
accord
previous
design
studi
inclus
criteria
determin
elig
disagr
resolv
third
investig
zal
two
research
independ
extract
record
desir
inform
enrol
studi
standard
form
recommend
cochran
inform
consist
author
public
year
studi
design
nct
popul
demograph
characterist
age
gender
etc
diseas
condit
eg
acut
physiolog
chronic
health
evalu
ii
apach
ii
type
influenza
treatment
detail
eg
use
antivir
drug
type
initi
dose
corticosteroid
score
simplifi
acut
physiolog
score
ii
sap
ii
sequenti
organ
failur
assess
sofa
outcom
measur
mortal
mv
day
icu
lo
rate
secondari
infect
abovement
inform
includ
public
contact
correspond
author
email
obtain
data
need
quantifi
measur
associ
opinion
two
collector
differ
decis
reach
consensu
consult
third
investig
reduc
risk
bia
studi
independ
assess
two
author
ynn
bml
newcastleottawa
scale
use
disagr
relat
qualiti
assess
resolv
consensu
addit
file
statist
analys
perform
present
studi
conduct
independ
statistician
use
cochran
systemat
review
softwar
review
manag
revman
version
nordic
cochran
centr
cochran
collabor
copenhagen
mannwhitney
u
test
perform
test
hypothesi
defin
statist
signific
z
valu
p
valu
result
display
forest
plot
continu
variabl
report
mean
standard
deviat
sd
dichotom
variabl
shown
frequenc
proport
statist
heterogen
test
test
qualifi
p
also
perform
sensit
analysi
substitut
altern
decis
rang
valu
decis
arbitrari
unclear
randomeffect
model
appli
presenc
statist
heterogen
continu
data
calcul
mean
differ
md
confid
interv
ci
dichotom
data
calcul
risk
ratio
rr
ci
also
perform
subgroup
analys
accord
viral
type
studi
compar
outcom
corticosteroid
noncorticosteroid
group
mortal
record
studi
mv
day
describ
three
studi
rate
secondari
infect
present
five
studi
icu
lo
report
two
studi
eight
studi
includ
patient
infect
one
includ
patient
infect
anoth
includ
patient
viral
abc
detail
enrol
studi
present
tabl
total
patient
pool
includ
trial
final
systemat
review
metaanalysi
among
patient
treat
corticosteroid
treat
noncorticosteroid
detail
baselin
characterist
patient
enrol
studi
shown
tabl
ascertain
qualiti
maximum
nine
point
assign
studi
four
select
two
compar
three
outcom
composit
score
regard
indic
high
qualiti
two
studi
rate
total
score
four
studi
score
four
studi
score
tabl
funnel
plot
show
evid
public
bia
signific
statist
heterogen
found
analysi
effect
corticosteroid
mortal
p
mv
day
p
rate
secondari
infect
p
patient
influenza
pneumonia
icu
lo
p
mortal
higher
patient
receiv
corticosteroid
rr
ci
z
p
similar
result
also
observ
subgroup
analysi
patient
rr
ci
z
p
fig
patient
viral
type
addit
file
corticosteroid
effect
mv
day
md
ci
z
p
fig
result
found
subgroup
analysi
addit
file
icu
lo
longer
corticosteroid
group
md
ci
z
p
fig
result
found
subgroup
analysi
addit
file
rate
secondari
infect
higher
patient
receiv
corticosteroid
ci
z
p
control
group
fig
result
found
subgroup
analysi
addit
file
present
systemat
review
metaanalysi
use
corticosteroid
increas
mortal
icu
lo
rate
secondari
infect
patient
influenza
pneumonia
influenc
mv
day
analysi
demonstr
corticosteroid
increas
mortal
also
prolong
icu
lo
sever
potenti
mechan
could
underli
higher
mortal
icu
lo
observ
patient
receiv
corticosteroid
first
corticosteroid
reduc
system
inflamm
attack
viru
immun
system
activ
corticosteroid
inhibit
immun
reaction
suppress
inflammatori
reaction
prevent
migrat
inflammatori
cell
circul
issu
suppress
synthesi
chemokin
cytokin
inhibit
immun
respons
mediat
cell
b
cell
thu
alter
immun
reaction
caus
corticosteroid
might
lead
prolong
viru
viremia
delay
viral
clearanc
ultim
increas
risk
mortal
one
includ
studi
show
patient
receiv
corticosteroid
lower
procalcitonin
level
vs
ngml
p
anoth
show
patient
die
higher
rate
immunosuppress
vs
p
second
analysi
found
patient
receiv
corticosteroid
like
develop
secondari
bacteri
pneumonia
due
immunosuppress
addit
longer
icu
lo
also
shown
contribut
secondari
infect
third
due
immunesuppress
effect
corticosteroid
risk
develop
critic
ill
increas
corticosteroidtr
patient
one
studi
found
rate
shock
corticosteroid
group
control
group
addit
invas
mv
rate
also
increas
corticosteroid
corticosteroid
group
control
group
fourth
corticosteroidrel
advers
outcom
cardiovascular
event
includ
fluid
retent
prematur
atherosclerot
diseas
arrhythmia
also
increas
mortal
patient
influenza
pneumonia
includ
studi
patient
use
vasopressor
higher
mortal
thu
mechan
may
contribut
patient
influenza
pneumonia
higher
mortal
also
perform
subgroup
analysi
accord
viral
type
type
influenza
viru
mortal
higher
treat
corticosteroid
control
although
symptom
rapidli
progress
patient
risk
ard
higher
patient
infect
moreov
includ
larg
sampl
studi
includ
previou
metaanalys
relat
influenza
addit
focus
patient
influenza
pneumonia
infect
influenza
alon
influenza
admit
icu
influenza
pneumonia
shown
relat
lifethreaten
respiratori
failur
mortal
howev
patient
infect
influenza
develop
influenza
pneumonia
present
studi
tri
determin
whether
patient
develop
influenza
pneumonia
benefit
corticosteroid
nevertheless
may
omit
patient
influenza
pneumonia
includ
trial
studi
influenza
patient
may
influenc
final
result
analysi
studi
explor
effect
corticosteroid
patient
communitybas
pneumonia
produc
posit
result
main
reason
find
infect
bacteria
benefit
corticosteroid
given
appropri
antibiot
therapi
earli
use
antivir
therapi
could
also
reduc
mortal
seven
studi
report
use
antivir
therapi
one
hand
explor
exact
role
antivir
therapi
effect
corticosteroid
due
lack
raw
data
hand
also
includ
patient
develop
influenza
pneumonia
result
includ
case
sever
includ
studi
patient
use
antivir
therapi
includ
moreov
patient
receiv
corticosteroid
like
superinfect
secondari
bacteri
pneumonia
invas
fungal
infect
exacerb
underli
condit
also
prolong
icu
lo
found
nocorticosteroid
group
addit
one
studi
show
use
corticosteroid
delay
initi
neuraminidas
inhibitor
icu
lo
longer
patient
receiv
neuraminidas
inhibitor
within
day
ill
term
mv
day
corticosteroid
seem
make
differ
howev
three
studi
analysi
report
data
mv
day
insignific
result
might
therefor
due
fact
small
sampl
size
word
type
ii
error
might
occur
limit
number
patient
aforement
reason
effect
corticosteroid
could
also
influenc
follow
three
factor
first
condit
respiratori
system
could
respons
corticosteroid
provid
benefit
patient
oxygen
index
oi
partial
arteri
pressur
oxygenfract
inspir
oxygen
may
also
increas
mortal
rate
oi
second
time
corticosteroid
initi
could
contribut
factor
compar
treatment
administr
within
first
day
strongli
associ
increas
risk
death
moreov
corticosteroid
benefici
use
earli
ard
onset
otherwis
increas
mortal
realiti
howev
patient
receiv
corticosteroid
ard
onset
offset
neg
effect
corticosteroid
mortal
third
dose
corticosteroid
may
affect
result
high
dose
corticosteroid
associ
greater
mortal
longer
durat
viral
shed
li
studi
mortal
twice
high
patient
receiv
high
dose
corticosteroid
receiv
lowmoder
dose
initi
dose
corticosteroid
vari
among
includ
studi
report
relat
inform
addit
due
studi
design
patient
one
studi
receiv
unifi
dose
corticosteroid
moreov
studi
shown
corticosteroid
usual
initi
shock
nonrespons
fluid
vasopressor
thu
patient
receiv
corticosteroid
tend
sever
diseas
evidenc
higher
apach
ii
score
therefor
unclear
whether
increas
risk
mortal
directli
associ
corticosteroid
use
due
sever
diseas
none
studi
includ
analysi
random
control
studi
rct
influenc
factor
could
control
analysi
highli
heterogen
might
explain
corticosteroid
make
differ
studi
despit
find
limit
studi
address
first
applic
studi
result
limit
none
studi
includ
analysi
rct
second
two
studi
report
dose
corticosteroid
durat
use
third
baselin
characterist
patient
influenc
outcom
vari
among
studi
includ
analysi
exampl
younger
age
fewer
underli
diseas
might
associ
fewer
secondari
infect
final
effect
corticosteroid
patient
influenza
pneumonia
remain
controversi
previou
studi
show
neg
effect
corticosteroid
may
influenc
clinician
use
corticosteroid
includ
studi
final
may
select
bia
none
studi
includ
rct
corticosteroid
could
increas
mortal
patient
influenza
pneumonia
random
control
studi
need
verifi
conclus
